Publications
2011
p53 lesions in leukemic transformation.
Harutyunyan A,
Klampfl T,
Cazzola M,
Kralovics R.
N Engl J Med. 2011 Feb 3;364(5):488-90.
2011
Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies.
Harutyunyan A,
Gisslinger B,
Klampfl T,
Berg T,
Bagienski K,
Gisslinger H,
Kralovics R.
Leukemia. 2011 Nov;25(11):1782-4.
2011
Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations – clinical relevance in the monitoring of polycythemia.
Carillo S,
Henry L,
Lippert E,
Girodon F,
Guiraud I,
Richard C,
Dubois Galopin F,
Cleyrat C,
Jourdan E,
Kralovics R,
Hermouet S,
Lavabre-Bertrand T.
J Mol Diagn. 2011 May;13(3):263-70.
2010
Molecular pathogenesis of Philadelphia chromosome-negative chronic myeloproliferative neoplasms.
Jager R,
Kralovics R.
Curr Cancer Drug Targets. 2010 Nov 10.
2010
Molecular basis and clonal evolution of myeloproliferative neoplasms.
Jager R,
Kralovics R.
Haematologica. 2010 Apr;95(4):526-9.
2010
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.
Jager R,
Gisslinger H,
Passamonti F,
Rumi E,
Berg T,
Gisslinger B,
Pietra D,
Harutyunyan A,
Klampfl T,
Olcaydu D,
Cazzola M,
Kralovics R.
Leukemia. 2010 Jul;24(7):1290-8. Epub 2010 May 27.
2009
Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.
Schaub FX,
Jäger R,
Looser R,
Hao-Shen H,
Hermouet S,
Girodon F,
Tichelli A,
Gisslinger H,
Kralovics R,
Skoda RC.
Blood, 2009 Feb;113(9):2022-7.
2009
The GGCC haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation positive polycythemia vera.
Olcaydu D,
Skoda RC,
Looser R,
Li S,
Cazzola M,
Pietra D,
Passamonti F,
Lippert E,
Carillo S,
Girodon F,
Vannucchi A,
Reading NS,
Prchal JT Ay C,
Pabinger I,
Gisslinger H,
Kralovics R.
Leukemia, 2009 Oct;23(10):1924-6. Epub 2009 May 14.
2009
A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms.
Olcaydu D,
Harutyunyan A,
Jäger R,
Berg T,
Gisslinger B,
Pabinger I,
Gisslinger H,
Kralovics R.
Nature Genetics, 2009 41(4):450-4. Epub 2009 Mar 15.
2009
Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofifibrosis.
Buxhofer-Ausch V,
Gisslinger H,
Berg T,
Gisslinger B,
Kralovics R.
Eur J Haematol, 2009 Feb;82(2):161-3.
